학술논문
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
Document Type
Article
Author
Pabst, T.; Papayannidis, C.; Demirkan, F.; Doronin, V.; Fogliatto, L.M.; Guttke, C.; Johnson, A.J.; Ma, X.; Gyan, E.; Hamad, N.; Herrera, P.; Hultberg, A.; Jacobs, J.; Langlois, A.; Martinelli, G.; Arnan, M.; Müller, R.; Nottage, K.; Tolbert, J.A.; Trudel, G.C.; Xiu, L.; Ofran, Y.; Özcan, M.; Samoilova, O.; Vey, N.; Wei, A.H.
Source
In: The Lancet Haematology . (The Lancet Haematology, November 2023, 10(11):e902-e912)
Subject
Language
English
ISSN
23523026